

Final Program

**Workshop of the
Paul Martini Foundation:
"Therapeutic oligonucleotides
in drug development"
Berlin-Brandenburg Academy
of Sciences**

Berlin, June 13-14, 2003

**Scientific advisory board
Prof. Dr. med. Stefan Endres
PD Dr. med. Gunther Hartmann
Dr. rer. nat. Klaus-Dieter Langner**

Welcome**13:00 Prof. Dr. Stefan Endres**

Division of Clinical Pharmacology
Ludwig-Maximilians-University of
Munich, Germany

Key note address**13:15 Prof. Dr. Georg Sczakiel**

Institute for Molecular Medicine
University Hospital Lübeck,
Germany
**Oligonucleotide therapeutics:
antisense, CpG and RNAi
- an overview**

Technology

Chair: Georg Sczakiel

14:00 Prof. Dr. Hermona Soreq

The Eric Roland Center for
Neurodegenerative Diseases
The Hebrew University of
Jerusalem, Israel
**The antisense nucleotide EN 101
retrieves cholinergic homeostasis:
from animal models to clinical
trials**

14:30 Dr. Beate Greiner

Aventis Pharma Deutschland
GmbH, Frankfurt, Germany
**Antisense oligonucleotides -
mechanism, chemistry and
therapeutics**

15:00 Dr. Volker Gekeler

Altana Pharma, Konstanz,
Germany
**Therapeutic activity of
oligo-nucleotides in murine
tumor models**

15:30 Dr. Marc LeMaitre

Eurogentec, Seraing, Belgium
**Production of GMP nucleic
acids**

16:00 Break**16:30 Prof. Dr. Hiroshi Takaku**

Chiba Institute of Technology,
Chiba, Japan
**Inhibition of HIV-1 in
leuko-cytes by long-dsRNA**

17:00 PD Dr. Arndt Borkhardt

Clinic for pediatrics,
University Giessen, Germany
**RNA interference in leukemia
and lymphoma**

17:30 Dr. Brian Sproat

RNA-TEC NV,
Leuven, Belgium
**RNA synthesis, purification
and analysis**

18:00 Prof. Peter E. Nielsen

Copenhagen University,
Denmark
**Control of gene expression by
peptide nucleic acids (PNA)**

18:30 Prof. Dr. Georg Sczakiel

Sum-up

20:00 Welcome reception

Clinical development I: CpG and antisense

Chair: Bernd Dörken

Key note address

8:30 PD Dr. Gunther Hartmann

Division of Clinical Pharmacology,
University of Munich, Germany
**Oligonucleotide therapeutics and the
immune system**

9:15 Prof. Dr. Stefan Endres

Division of Clinical Pharmacology,
University of Munich, Germany
**The use of CpG oligonucleo-tides for
immunotherapy of cancer**

9:45 Dr. Christian Schetter

Coley Pharmaceutical Group,
Langenfeld, Germany
**Recent progress in the understanding
and clinical development of immunomod-
ulatory oligonucleotides**

10:15 Break

10:45 Prof. Dr. Burkhard Jansen

OncoGenex Technologies, Inc.,
Vancouver, Canada
**Clusterin antisense - of mice and
men**

11:15 Dr. Ingo Tamm

University Hospital Charité
Humboldt-University Berlin, Germany
**Antisense in hematology and
oncology**

11:45 Dr. Volker Wacheck

AKH, University of Vienna,
Austria
**The antisense oligonucleotide
G3139**

12:15 Dr. Peter Hau

Dept. of Neurology, University of
Regensburg, Germany
**TGF-beta-2 Antisense therapy
in recurrent high-grade glioma
patients**

12:45 Lunch break

Clinical development II: RNA and regulatory aspects

Chair: Fritz Eckstein

14:00 Dr. Stefan Limmer

Ribopharma AG,
Kulmbach, Germany
**Towards the development of
therapeutics on the basis of
small synthetic double-
stranded RNA-duplexes**

14:30 Prof. Dr. Klaus Cichutek

Paul Ehrlich Institute,
Langen, Germany
**Regulatory aspects of
gene transfer of medicinal
products**

Concluding remarks and panel discussion

15:00 Chair: Prof. Dr. Fritz Eckstein

Max Planck Institute for
Experimental Medicine,
Göttingen, Germany
Sum-up and future directions

15:30 End of Workshop